Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06119789 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Precision Cancer Therapy in Rare Cancers

Study acronym: MATRIX-Rare
StatusRecruiting
PhasePhase 2
Started2025-03-20
View on ClinicalTrials.gov ↗

Amendment history

2025-03-23
Not Yet Recruiting→Recruiting Study Status, Arms and Interventions, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2028-11→2033-11-30
Completion date2033-08→2036-08-01
Start dateestimated 2024-08→confirmed 2025-03-20
Study sites0→1
InterventionsImatinib (Drug)→Dabrafenib (Drug), Imatinib (Drug), Trametinib (Drug)
2024-05-27
Study Status v1
Primary completion date2027-11→2028-11
Start date2023-11→2024-08
2023-11-01
Original filing
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Trial Details
NCT Number NCT06119789
Lead Sponsor Oslo University Hospital
Collaborators: Helse Stavanger HF, University Hospital of North Norway, StOlavs Hospital, Nordlandssykehuset HF, Helse Nord-Trøndelag HF, Sorlandet Hospital HF, Møre og Romsdal Hospital Trust, The Hospital of Vestfold, Helse Fonna, Haukeland University Hospital, Sykehuset Ostfold, Helse Forde, Sykehuset Innlandet HF
Conditions Rare Malignant Neoplasm
Enrollment 96 participants
Start Date 2025-03-20
Primary Completion 2033-11-30 (estimated)
Study Completion 2036-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-26